Study Design Overview and Imputation of Cell Viability from PRISM.

(A) Flow chart showing data source collection, integration and modeling strategy. (B) Sample imputed cell viability curves for all assayed cell lines (gray underlying lines) and corresponding average imputed cell viability response (blue line) for three compounds showing low changes (Motesanib), medium level changes (AZD-2014) and high changes (SB-1317) in cell viability. (C) Overall distribution of cell viability values imputed at Klaeger et al compound concentrations. (D) Distribution of imputed cell viability across all concentrations for a selection (60 out of 168) sampled evenly across the average imputed cell viability effect of the compounds present in both PRISM and the Klaeger et al set. The blue and green color scheme does not indicate anything about the underlying data and is meant to act as a visual aid for differentiating between adjacent curves. (Panel A was created with BioRender.com).